{"prompt": "['Protocol', 'BioCryst Pharmaceuticals, Inc.', 'Version 3.0', 'CONFIDENTIAL', 'BCX7353-302', 'During the Part 2 dosing period, Investigators will contact subjects to confirm all HAE attacks', 'recorded in the e-diary within approximately 2 business days of the end of the attack. Moreover,', 'any noncompliance will warrant contact with the subject.', '10.3.4.', 'Part 2', '10.3.4.1. Week 26 Visit', 'The Week 26 visit ( 2 days) will consist of monitoring liver function tests only (ALT, AST,', 'GGT, total and direct bilirubin, ALP); urine and additional tubes of blood may be required to', 'accommodate reflex testing for abnormal GGT, AST, or ALT (see Table 5). If preferred by the', 'subject and clinical site, laboratory values may be drawn and resulted locally, with results', 'entered into the CRF.', 'During the Part 2 dosing period, Investigators will contact subjects to confirm all HAE attacks', 'recorded in the e-diary within approximately 2 business days of the end of the attack. Moreover,', 'any noncompliance will warrant contact with the subject.', '10.3.4.2. Week 28, 32, 36, and 48 Visits', 'Subjects will return to the clinic during Week 28 (Day 197 2 days), Week 32 (Day 225', '2 days), Week 36 (Day 253 2 days), and Week 48 (Day 337 + 7 days).', 'The Week 48 visit will be conducted on Day 337 (+7 days). Subjects do not need to withhold', 'any doses for the Week 28, 32, or 36 visits or take a dose in the clinic, unless the clinic visit falls', \"during the subject's normal time of dosing.\", 'The following assessments will be performed:', 'Administration of EQ-5D-5L (1 or 2 questionnaires), AE-QoL, TSQM, and WPAI', 'questionnaires. Where possible, the questionnaires should be completed by the', 'subject prior to other assessments to prevent influencing subject perceptions.', 'Subject weight', 'Vital signs (blood pressure and pulse rate)', '12-lead ECG (single assessments)', 'Abbreviated physical examination (targeted to new signs and symptoms)', 'Blood collection for clinical chemistry, hematology, and coagulation, Troponin I and', 'Troponin T, NGAL, and CK-MB', 'PK and PD plasma samples', 'Urine collection for urinalysis, possible reflex testing for abnormal GGT, AST, or', 'ALT and urine pregnancy test for female subjects of child-bearing potential', 'Review of concomitant medications and AEs', 'Review of HAE attack and dosing diary completion and study drug compliance', 'Study drug accountability and dispensing', '68']['Protocol', 'BioCryst Pharmaceuticals, Inc.', 'Version 3.0', 'CONFIDENTIAL', 'BCX7353-302', 'During the Part 2 dosing period, Investigators will contact subjects to confirm all HAE attacks', 'recorded in the e-Diary within approximately 2 business days of the end of the attack. Moreover,', 'any noncompliance will warrant contact with the subject.', 'At the Week 36 and 48 visits, sites in Europe will dispense urinary pregnancy tests to subjects', 'who are women of childbearing potential. These will be performed by the subject at home at', 'Weeks 40, 44, 52, and 56.', '10.3.4.3. Week 40 and 44 Phone calls', 'The Investigator (or designee) must call and talk to the subject once during Weeks 40 and 44;', 'alternative forms of interactive communication such as returned email and cellular text', 'correspondence are acceptable. During all calls, the Investigator (or designee) will assess the', \"subject's overall wellbeing, discuss compliance (if applicable), proper recording of attack details\", '(if applicable), or any usability issues with the e-diary. The phone call may be omitted if the', 'subject records an attack as the Investigator must call and confirm or reject the attack.', '10.3.5.', 'Part 3', '10.3.5.1. Week 60, 72, 84, and 96, 108, 120, 132, and 144 Visits', 'Subjects will return to the clinic for additional study visits for up to 144 weeks, until another', 'mechanism is available to provide drug to the subject, or until the Sponsor discontinues', 'development of the product for the prevention of angioedema attacks, whichever comes first.', 'Study visits are planned to occur at Week 60 (Day 421 6 days), Week 72 (Day 505 6 days),', 'Week 84 (Day 589 6 days), Week 96 (Day 673 6 days), Week 108 (Day 757 6 days), Week', '120 (Day 841 6 days), Week 132 (Day 925 6 days), and Week 144 (Day 1009 6 days)', 'Subjects do not need to withhold any doses on clinic days or take a dose in the clinic, unless the', \"clinic visit occurs during the subject's normal time of dosing.\", 'The following assessments will be performed:', 'Administration of EQ-5D-5L (1 or 2 questionnaires), AE-QoL, TSQM, and WPAI', 'questionnaires. Long-term experience on study will be assessed every 24 weeks', 'beginning at Week 96 via brief questionnaire. After Week 96, EQ-5D-5L, TSQM and', 'WPAI will be administered every 24 weeks (Weeks 120 and 144) and at end-of-study', 'visit. Where possible, the questionnaires should be completed by the subject prior to', 'other assessments to prevent influencing subject perceptions.', 'Subject weight (adolescent subjects will also have height measured at Weeks 96 and', '144)', 'Vital signs (blood pressure and pulse rate)', '12-lead ECG (single assessments)', 'Abbreviated physical examination (targeted to new signs and symptoms)', 'Blood collection for clinical chemistry, hematology, and coagulation, Troponin I and', 'Troponin T, NGAL, and CK-MB', '69']\n\n###\n\n", "completion": "END"}